At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Hepatocellular Carcinoma. Completed, enrolled 29 participants across 1 site.
Detailed Summary
This is a single-arm phase II trial of Pembrolizumab (Keytruda) in patients with advanced, unresectable hepatocellular carcinoma. The primary objective is to assess its therapeutic efficacy in patients with unresectable hepatocellular carcinoma (HCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMay 2016
Primary CompletionNov 2019
Study CompletionDec 2019
TodayJul 2026
First PostedJan 18, 2016
Enrollment StartMay 6, 2016
Primary CompletionNov 10, 2019
Study CompletionDec 17, 2019
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 10.5 years ago
Interventions
Pembrolizumabdrug
Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.